Gerhard DM, Wohleb ES, Duman RS (2016) Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today 21:454–464. https://doi.org/10.1016/j.drudis.2016.01.016
Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563–569. https://doi.org/10.1016/j.tips.2009.09.002
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. https://doi.org/10.1016/s0006-3223(99)00230-9
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864. https://doi.org/10.1001/archpsyc.63.8.856
Henter ID, Park LT, Zarate CA Jr (2021) Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs 35:527–543. https://doi.org/10.1007/s40263-021-00816-x
Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271:577–582. https://doi.org/10.1007/s00406-020-01110-5
Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632. https://doi.org/10.1038/tp.2015.136
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237. https://doi.org/10.1146/annurev.pharmtox.37.1.205
Schoepp DD, Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13–20. https://doi.org/10.1016/0165-6147(93)90107-u
Schaffhauser H, Richards JG, Cartmell J, Chaboz S, Kemp JA, Klingelschmidt A, Messer J, Stadler H, Woltering T, Mutel V (1998) In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain. Mol Pharmacol 53:228–233
Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4–15. https://doi.org/10.1038/npp.2011.181
Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036
Palucha A, Pilc A (2007) Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 115:116–147. https://doi.org/10.1016/j.pharmthera.2007.04.007
Kenny PJ, Markou A (2004) The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 25:265–272. https://doi.org/10.1016/j.tips.2004.03.009
Kinon BJ, Millen BA, Zhang L, McKinzie DL (2015) Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 78:754–762. https://doi.org/10.1016/j.biopsych.2015.03.016
Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33:1603–1610. https://doi.org/10.1038/sj.npp.1301531
Jing XY, Wang Y, Zou HW, Li ZL, Liu YJ, Li LF (2021) mGlu2/3 receptor in the prelimbic cortex is implicated in stress resilience and vulnerability in mice. Eur J Pharmacol 906:174231. https://doi.org/10.1016/j.ejphar.2021.174231
Kawasaki T, Ago Y, Yano K, Araki R, Washida Y, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2011) Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology 60:397–404. https://doi.org/10.1016/j.neuropharm.2010.10.009
Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PB, Hasler G, Stockmeier CA, Iyo AH, Karolewicz B (2010) Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 34:279–283. https://doi.org/10.1016/j.pnpbp.2009.11.018
McOmish CE, Pavey G, Gibbons A, Hopper S, Udawela M, Scarr E, Dean B (2016) Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. J Affect Disord 190:241–248. https://doi.org/10.1016/j.jad.2015.10.004
Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F (2013) L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110:4804–4809. https://doi.org/10.1073/pnas.1216100110
Wierońska JM, Legutko B, Dudys D, Pilc A (2008) Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol Rep 60:844–855
Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A (2014) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457–467. https://doi.org/10.1016/j.neuropharm.2003.10.009
Witkin JM, Ornstein PL, Mitch CH, Li R, Smith SC, Heinz BA, Wang XS, Xiang C, Carter JH, Anderson WH, Li X, Broad LM, Pasqui F, Fitzjohn SM, Sanger HE, Smith JL, Catlow J, Swanson S, Monn JA (2017) In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist. Neuropharmacology 115:100–114. https://doi.org/10.1016/j.neuropharm.2015.12.021
Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I, Schneider M, Legrand C, Parron D, Girard F, Bessif A, Poli S, Vaugeois JM, Le Poul E, Celanire S (2011) Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet 25:152–166. https://doi.org/10.3109/01677063.2011.627485
Lavreysen H, Langlois X, Ahnaou A, Drinkenburg W, te Riele P, Biesmans I, Van der Linden I, Peeters L, Megens A, Wintmolders C, Cid JM, Trabanco AA, Andrés JI, Dautzenberg FM, Lütjens R, Macdonald G, Atack JR (2013) Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther 346:514–527. https://doi.org/10.1124/jpet.113.204990
Chaki S (2017) mGlu2/3 receptor antagonists as novel antidepressants. Trends Pharmacol Sci 38:569–580. https://doi.org/10.1016/j.tips.2017.03.008
Witkin JM (2020) mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects. Pharmacol Biochem Behav 190:172854. https://doi.org/10.1016/j.pbb.2020.172854
Dong C, Zhang JC, Yao W, Ren Q, Ma M, Yang C, Chaki S, Hashimoto K (2017) Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int J Neuropsychopharmacol 20:228–236. https://doi.org/10.1093/ijnp/pyw089
Dong C, Tian Z, Fujita Y, Fujita A, Hino N, Iijima M, Hashimoto K (2022) Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: comparison with escitalopram. Pharmacol Biochem Behav 212:173316. https://doi.org/10.1016/j.pbb.2021.173316
Dwyer JM, Lepack AE, Duman RS (2013) mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 1:15. https://doi.org/10.1186/2049-9256-1-15.eCollection2013
Pałucha-Poniewiera A, Podkowa K, Rafało-Ulińska A (2021) The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice. Prog Neuropsychopharmacol Biol Psychiatry 109:110239. https://doi.org/10.1016/j.pnpbp.2020.110239
Seo MK, Lee JA, Jeong S, Seog DH, Lee JG, Park SW (2022) Effects of chronic LY341495 on hippocampal mTORC1 signaling in mice with chronic unpredictable stress-induced depression. Int J Mol Sci 23:6416. https://doi.org/10.3390/ijms23126416
Koike H, Iijima M, Chaki S (2013) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav 107:20–23. https://doi.org/10.1016/j.pbb.2013.03.017
Highland JN, Zanos P, Georgiou P, Gould TD (2019) Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology 44:1788–1796. https://doi.org/10.1038/s41386-019-0380-1
Witkin JM, Monn JA, Li J, Johnson B, McKinzie DL, Wang XS, Heinz BA, Li R, Ornstein PL, Smith SC, Mitch CH, Calligaro DO, Swanson S, Allen D, Phillips K, Gilmour G (2017) Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects. Pharmacol Biochem Behav 155:43–55. https://doi.org/10.1016/j.pbb.2017.03.001
Goeldner C, Ballard TM, Knoflach F, Wichmann J, Gatti S, Umbricht D (2013) Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 64:337–346. https://doi.org/10.1016/j.neuropharm.2012.08.001
Shimazaki T, Kaku A, Chaki S (2007) Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol 575:94–97. https://doi.org/10.1016/j.ejphar.2007.08.006
留言 (0)